Urokinase-type plasminogen activator and its specific receptor in high metastatic and non-metastatic cell lines derived from human lung adenocarcinoma
- 1 February 1992
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 65 (3) , 449-456
- https://doi.org/10.1016/0049-3848(92)90175-a
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Plasminogen activator inhibitor 1 in human carcinoma tissuesInternational Journal of Cancer, 1991
- Human lung adenocarcinoma cell lines with different lung colonization potential (LCP), and a correlation between expression of sialosyl dimeric Lex (defined by MAb FH6) and LCPClinical & Experimental Metastasis, 1991
- Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cellsClinical & Experimental Metastasis, 1991
- Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.Cell Regulation, 1990
- Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNABlood, 1990
- The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.The Journal of cell biology, 1990
- Absence of t-PA in spontaneous metastatic lesions induced by a newly established cell lineThrombosis Research, 1989
- Plasminogen activator inhibitorsBlood, 1987
- Plasminogen Activators, Tissue Degradation, and CancerPublished by Elsevier ,1985
- On the Regulation and Control of FibrinolysisThrombosis and Haemostasis, 1980